Wyeth's Sales Tactics Not Anti-Competitive: Court

Law360, New York (May 11, 2007, 12:00 AM EDT) -- A group of pharmaceutical wholesalers has lost an appeal brought against Wyeth-Ayerst Laboratories over claims the drug maker hiked up the price of its hormone medication while keeping its competitor out of the lucrative market.

The U.S. Court of Appeals for the Sixth Circuit on Thursday affirmed a lower court’s granting of summary judgment to Wyeth, ruling the company had not violated federal antitrust laws despite the aggressive tactics it used to boost sales of Premarin at the expense of rival company Duramed.

The class of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.